Copyright investors
The Relative Strength (RS) Rating for AstraZeneca ADR (AZN) entered a higher percentile Wednesday, as it got a lift from 70 to 78. This exclusive rating from Investor's Business Daily identifies market leadership with a 1 (worst) to 99 (best) score. The score shows how a stock's price performance over the last 52 weeks stacks up against all the other stocks in our database. History reveals that the best-performing stocks tend to have an RS Rating north of 80 in the early stages of their moves. See if AstraZeneca ADR can continue to rebound and clear that threshold. AstraZeneca ADR broke out earlier, but has fallen back below the prior 82.41 entry from a cup with handle. If a stock you're tracking clears a buy point then falls 7% or more below the original entry price, it's considered a failed base. Wait for the stock to set up and breakout from a new base and entry price. Also keep in mind that the most recent consolidation is a later-stage base, which makes it riskier to establish a new position or add shares to an existing one. Earnings growth declined in the most recent report from 21% to 10%. But revenue moved higher, from 7% to 12%. The company is expected to report its latest numbers on or around Nov. 6. The company earns the No. 3 rank among its peers in the Medical-Diversified industry group. Eli Lilly (LLY) is the top-ranked stock within the group. This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
